These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27531281)

  • 1. HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival.
    Koirala P; Roth ME; Gill J; Chinai JM; Ewart MR; Piperdi S; Geller DS; Hoang BH; Fatakhova YV; Ghorpade M; Zang X; Gorlick R
    Sci Rep; 2016 Aug; 6():31154. PubMed ID: 27531281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients.
    Xia C; Huang W; Chen YL; Fu HB; Tang M; Zhang TL; Li J; Lv GH; Yan YG; Ouyang ZH; Yao N; Wang C; Zou MX
    Front Immunol; 2021; 12():797407. PubMed ID: 35145510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
    Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
    J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
    Chen Y; Hu R; Li X; Shi Z; Tian H; Feng J; Yu S
    Pathol Res Pract; 2020 Oct; 216(10):153134. PubMed ID: 32853956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
    Zhou QH; Li KW; Chen X; He HX; Peng SM; Peng SR; Wang Q; Li ZA; Tao YR; Cai WL; Liu RY; Huang H
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
    Lussier DM; O'Neill L; Nieves LM; McAfee MS; Holechek SA; Collins AW; Dickman P; Jacobsen J; Hingorani P; Blattman JN
    J Immunother; 2015 Apr; 38(3):96-106. PubMed ID: 25751499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
    Toda Y; Kohashi K; Yamada Y; Yoshimoto M; Ishihara S; Ito Y; Iwasaki T; Yamamoto H; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2607-2620. PubMed ID: 32388585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
    Koirala P; Roth ME; Gill J; Piperdi S; Chinai JM; Geller DS; Hoang BH; Park A; Fremed MA; Zang X; Gorlick R
    Sci Rep; 2016 Jul; 6():30093. PubMed ID: 27456063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
    Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
    Long L; Zhang L; Yang Y; Zhou Y; Chen H
    Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
    Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
    Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
    Liao X; Zhang D
    Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
    Wang B; Ran Z; Liu M; Ou Y
    Front Immunol; 2019; 10():1573. PubMed ID: 31379814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death ligand 1 expression in osteosarcoma.
    Shen JK; Cote GM; Choy E; Yang P; Harmon D; Schwab J; Nielsen GP; Chebib I; Ferrone S; Wang X; Wang Y; Mankin H; Hornicek FJ; Duan Z
    Cancer Immunol Res; 2014 Jul; 2(7):690-698. PubMed ID: 24866169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
    Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
    Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
    Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
    Front Immunol; 2022; 13():902167. PubMed ID: 36003385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
    Janakiram M; Chinai JM; Fineberg S; Fiser A; Montagna C; Medavarapu R; Castano E; Jeon H; Ohaegbulam KC; Zhao R; Zhao A; Almo SC; Sparano JA; Zang X
    Clin Cancer Res; 2015 May; 21(10):2359-66. PubMed ID: 25549724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
    Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
    Front Immunol; 2022; 13():984172. PubMed ID: 36159808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.